Last reviewed · How we verify
Nonavalent HPV vaccine
The nonavalent HPV vaccine developed by Xiamen University is currently marketed, positioning it as a key player in the prevention of HPV-related diseases. A significant competitive advantage is the key composition patent, which is set to expire in 2028, providing a period of market exclusivity. The primary risk is the potential increase in competition post-patent expiry, which could impact market share and revenue.
At a glance
| Generic name | Nonavalent HPV vaccine |
|---|---|
| Also known as | Gardasil9 |
| Sponsor | Xiamen University |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After HPV Vaccination (PHASE2)
- Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants (PHASE2)
- Testing RG1-VLP Vaccine to Prevent HPV-related Cancers (PHASE1)
- Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial (PHASE4)
- Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines (PHASE4)
- Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia (PHASE2)
- Clinical Trial Evaluating Secondary HPV Vaccination After Treatment of High-grade Cervical Lesions (PHASE2)
- Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nonavalent HPV vaccine CI brief — competitive landscape report
- Nonavalent HPV vaccine updates RSS · CI watch RSS
- Xiamen University portfolio CI